The market exclusivity period for new drugs in Japan: Overview of intellectual property protection and related regulations

Journal of Generic Medicines

Volumn 5, Issue 2, 2008, Pages 121-130

  Masuda, Sachiko ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

COST BENEFIT ANALYSIS; COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; HEALTH INSURANCE; JAPAN; LICENSING; MARKET; PATENT; POSTMARKETING SURVEILLANCE; REVIEW;

EID: 38049021109     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/palgrave.jgm.4950103     Document Type: Review

References (25)

1. WHO Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) (2006). Public Health, Innovation and Intellectual Property Right, World Health Organization, Geneva.
2. In this paper, 'a new drug' is defined as a new chemical entity (NCE) or new molecular entity (NME).
3. Ozima, A. (1999). Commentary of the TRIPS Agreement, Japan Machinery Center for Trade and Investment, Tokyo.
4. TRIPS and pharmaceutical patents. World Trade Organization, FACT SHEET, September 2006 .
5. Pub. L. No. 98-417, 98 Star. 1585 (1984).
6. Official Journal L 015, 17/01/1987 P. 0036-0037.
7. OJ No L 182, 02/07/1992, p.0001-0005.
8. COM(90)101final, para 19.
9. Supreme Court Judgment in 1999 (Ju) No. 153.
10. Iwata, H., Sabro, D. & Katsutada, A.(1975). Knowledge of Product Patents, Research Institute of Economy, Trade and Industry, Tokyo, p. 345.
11. Japanese Patent Office (JPO) (1984). The Impact of Product Patent Protection for Materials on the Chemical Industry in Japan, JPO, Tokyo, p. 14.
12. Strategic Council on Intellectual Property, Document1 'the Situation of New Drug Approvals after Introduction of Product Patent Protection System', the 7th meeting of Task Force on the Protection of Patents of Medical-Related Acts, 3rd June 2004 .
13. Supreme Court Judgment in 1998 (Gyo Hi) No. 43, 44.
14. JPO. Examination Guidelines for Patent and Utility Model, Part IV Patent Term Extension, JPO, Tokyo.
15. Notification No. 725 of PAB dated 25th August, 1993, Notification No. 041001 of PFSB dated 1st April, 2007.
16. English Regulatory Taskforce (2007). Pharmaceutical Administration and Regulation in Japan, JPMA, Tokyo, p. 128 .
17. Pub. L. 87-781 76 Scat. 780 (1962) This amendment in the US was a response to the Thalidomide tragedy in Europe.
18. The Strategic Council on Intellectual Property (2005). Intellectual Property Strategic Program 2005, Intellectual Property Policy Headquarter, Tokyo, p. 51 .
19. Nikkan-Yakughou (No. 11506), 19th April 2005.
20. Someno, K. (1988). Operation to patented invention in experiment and research. AIPPI 33(3), 141.
21. Strategic Council on Intellectual Property (2004). The issues on smooth utilization of patented invention. Working Group on Planning to Patent Strategic Policy, November 2004, p. 45.
22. Masuda, S. (2005). Current issues on patent protection on pharmaceuticals - Analyzing of patent effective life. Management of Intellectual Property 35(13), 1913.
23. 'Generic competition and Drug Prices', FDA website .
24. US Department of Commerce International Trade Administration (2004). Pharmaceutical Price Controls in OECD Countries; Implications for US Consumers, Pricing, Research and Development, and Innovation, US Department of Commerce International Trade Administration, Washington DC, 15 figure 3, 22 figure 9.
25. Riku, J. (2005). Current situation for generic drugs in Japan. Journal of Generic Medicine 23, 229 table 8.